DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Aakaar Medical Technologies Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 2 hrs ago·13 Oct 2026, 1:46 pm

Aakaar Medical Techno

Aakaar Medical Technologies Limited has informed the stock exchanges that it has obtained a certificate under SEBI's Depositories and Participants Regulations, 2018. This regulatory compliance confirms that the company has fulfilled the necessary requirements to function as a Depository Participant.

This development is a routine administrative milestone for the company. For investors, it signifies that Aakaar Medical Technologies is fully compliant with regulatory norms, which helps maintain transparency and governance standards. It is a positive signal regarding the company's adherence to market rules.

Investors should monitor the company's future quarterly results and operational updates. While this compliance is a necessary step for business operations, its direct impact on short-term stock price movement is likely to be minimal. Focus should remain on the company's core business performance.